Detalhe da pesquisa
1.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
N Engl J Med
; 385(24): 2252-2263, 2021 12 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34449181
2.
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.
Nephrol Dial Transplant
; 2024 Jun 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38858818
3.
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
Diabetes Obes Metab
; 26(1): 191-200, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37814928
4.
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Circulation
; 145(6): 437-447, 2022 02 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34775784
5.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
N Engl J Med
; 383(23): 2219-2229, 2020 Dec 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33264825
6.
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
Am J Nephrol
; 54(9-10): 370-378, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37708857
7.
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
J Am Soc Nephrol
; 33(1): 225-237, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34732509
8.
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Eur Heart J
; 43(6): 474-484, 2022 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35023547
9.
Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy.
Int J Mol Sci
; 24(3)2023 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-36768656
10.
Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
Int J Mol Sci
; 24(3)2023 Jan 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36768859
11.
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Circulation
; 143(6): 540-552, 2021 02 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33198491
12.
Molecular mechanisms and therapeutic targets for diabetic kidney disease.
Kidney Int
; 102(2): 248-260, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35661785
13.
Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage.
Am J Nephrol
; 53(7): 552-564, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35675794
14.
Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells.
FASEB J
; 35(2): e21314, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33417258
15.
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Nephrol Dial Transplant
; 37(6): 1014-1023, 2022 05 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33280027
16.
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Eur Heart J
; 42(2): 152-161, 2021 01 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33099609
17.
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
Int J Mol Sci
; 23(16)2022 Aug 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36012508
18.
Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.
J Card Fail
; 27(2): 233-241, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33188886
19.
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
Am J Nephrol
; 52(8): 642-652, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34111864
20.
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
Am J Nephrol
; 52(7): 588-601, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34515038